Midatech Pharma PLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Midatech Pharma PLC
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- DARA BioSciences, Inc.
- MidaSol Therapeutics LP
- Midatech Group Ltd.
- Oncogenerix, Inc.
- Pharmida AG
- Point Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.